Ordinal Scale – Page 4 – Communicable Diseases Research

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

중증 COVID-19가 있는 성인의 회복기 혈장에 대한 무작위 이중 맹검 대조 시험

Clinical Trial

Published on 2021-07-012022-09-11
Journal: The Journal of Clinical Investigation [Category] SARS, 변종, 임상, 진단, 치료기술,

Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial

초기 SARS-CoV-2 Q-PCR 양성 고위험 개인(RES-Q-HR)의 회복기 혈장/카모스타트 메실레이트: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-05-172022-08-31
Journal: Trials [Category] SARS, 임상, 치료기술, 치료제,

[키워드] accommodation acts Administered administration Adult patients Adverse adverse events alcohol Alcohol Abuse ALT anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anticancer Antiviral antiviral therapy appearance approved AST blinded Blinding BMI body weight Bone marrow Breastfeeding CAD camostat Camostat mesylate Capsule Care Caregivers Cell Child chronic Chronic kidney disease chronic obstructive pulmonary disease chronic obstructive pulmonary disease (COPD) cirrhosis CKD clinical clinical condition Compliance Concomitant concurrent conducted control group Controlled trial convalescent plasma COPD Coronary artery Coronary artery disease cough COVID-19 COVID-19 pneumonia criteria cumulative defined diabetes Diabetes Mellitus diagnosed diagnosis of SARS-CoV-2 diarrhea disease Disease progression disease stage disorder dissemination double-blind Duration early disease Early phase of SARS-CoV-2 infection Efficacy element enrolled Enrollment enrolment EudraCT evaluate evening event evidence of Exanthema excluded exclusion criteria fatigue Fever fibrosis Germany GFR half-live headache high risk higher risk Hospitalization Hospitalized host cell hypersensitivity IgA deficiency immunization Inclusion inclusion criteria increased risk independent individual Infection infection with SARS-CoV-2 Influenza influenza A Informed consent inhibitor institution intervention arm intervention arms Kidney disease less Life expectancy likelihood Liver cirrhosis Local local Ethics Committee Mask mesylate moderate mother multicenter nasal nasal cannula Neutralizing number objective Obstructive obstructive pulmonary disease Older Ordinal Scale organ outcome outcomes oxygen oxygen demand Pancreatitis parallel group participant Participants passive immunization Patient patients hospitalized PCR Placebo plasma Plasma transfusion Pneumonia positive pregnant women Presence Prevent prevent disease progression primary endpoint progression protocol pulmonary disease pulmonary fibrosis Q-PCR randomization Randomized Randomized controlled trial receive recruitment reduce Regulatory reported risk factor safety monitoring committee Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR screening visit Serine serine protease TMPRSS2 Serious Adverse Event Serious Adverse Events severe COVID-19 Shortness of breath SOC sore throat Stage Standard Standard of care stratified Stress Study protocol supplementary material Symptom symptom duration Symptoms tertiary care center tested the cell titers TMPRSS2 transfusion reaction Treatment treatment arm Trial Trial registration Tumor typical symptom typical symptoms ULN virus website WHO with COVID-19 women working hypothesis written Informed Consent
[DOI] 10.1186/s13063-021-05181-0 PMC 바로가기 [Article Type] Letter

Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching

2019년 중국 우한에서 발생한 중증 코로나바이러스 질환 환자에서 한약 과립의 효과 및 안전성: 성향 점수 매칭을 통한 후향적 단일 센터 연구

Article

Published on 2021-05-012022-08-31
Journal: Phytomedicine : international journal of phytother [Category] 치료제,

[키워드] 1:1 28-day mortality baseline category caused Chinese Chinese herbal medicine CHM Clinical improvement Computerized tomography coronavirus disease Coronavirus disease 2019 cough COVID-19 D-dimer level Day defined duration of fever Dyspnea Effect Fever fibrinolysis Granule granules Health herbal medicine high risk hospital lung lung lesion male no significant difference Ordinal Scale Patient patients treated Primary outcome propensity score matching PSM reduced retrospective Retrospective study severe coronavirus disease severe COVID-19 significant difference single-center single-center study the patient Treatment treatment effect usual care usual care alone was used Wuhan
[DOI] 10.1016/j.phymed.2020.153404 PMC 바로가기 [Article Type] Article

An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients

중증 COVID-19 환자에서 클로로퀸/하이드록시클로로퀸의 효능을 평가하는 공개 라벨 무작위 대조 시험

Clinical Trial

Published on 2021-04-272022-08-13
Journal: Scientific Reports [Category] MERS, SARS, 임상, 치료제,

[키워드] 105 patient 105 patients 9-point ordinal scale acute renal dysfunction acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 added Administered all-cause mortality analyzed arrythmia Arrythmias Brazil cardiovascular complication cardiovascular complications Chloroquine chloroquine/hydroxychloroquine Clinical outcome clinical status Combination coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 doubt drugs Effect Effects Efficacy enrolled evaluate FIVE Follow-up form hospital Hydroxychloroquine incidence increased risk intention to treat intervention group Invasive mechanical ventilation KDIGO mITT Odds ratio once daily Open-label Ordinal Scale outcomes Patient patients hospitalized positive RT-PCR Primary outcome randomization Randomized Randomized controlled trial Registered renal dysfunction respiratory risk risk ratio Sample size SARS-CoV-2 secondary outcome severe acute respiratory syndrome Coronavirus severe COVID-19 severe COVID-19 patient severe renal dysfunction standard care standard treatment the disease Treatment Trial Trial registration were assessed worsening
[DOI] 10.1038/s41598-021-88509-9 PMC 바로가기 [Article Type] Clinical Trial

Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial

중증 COVID-19에서 인터페론 요법의 역할: COVIFERON 무작위 대조 시험

Randomized Controlled Trial

Published on 2021-04-132022-08-13
Journal: Scientific Reports [Category] MERS, SARS, 바이오마커, 임상, 치료제,

[키워드] 95% CI adverse events Arm assigned benefit Chest CT scans clinical Clinical improvement clinical seven-step ordinal scale ClinicalTrials.gov, NCT04343768 conducted control group Controlled trial CT scan defined discharge Effect Enrollment FIVE Hydroxychloroquine IFNs IFNα IFNβ IFNβ1a IFNβ1b improvement indicated individually-randomized injection intention-to-treat population interferon interferons intervention group laboratory-confirmed SARS-CoV-2 infection Lopinavir Lopinavir/ritonavir median Mortality NCT04343768 no significant difference no significant differences Open-label Ordinal Scale P-value Patient positive positive RT-PCR Previous studies previous study primary outcome measure randomization Randomized controlled trial Randomly reduction in Registration registration number Respiratory tract diseases Ritonavir role SARS-COV-2 infection Seven severely ill patient significant difference single dose subcutaneous injections therapeutic therapy time Trial Registration Number TTCI twice a day type 1 interferon type 1 interferons Viral viral infections
[DOI] 10.1038/s41598-021-86859-y PMC 바로가기 [Article Type] Randomized Controlled Trial

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

경증 또는 중등도의 COVID-19 폐렴으로 입원한 환자를 위한 염증 신호 억제제(MATIS)의 다군 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-122022-09-10
Journal: Trials [Category] 임상,

[키워드] 24 hours accounted Administered age agreement All participants Allergic reactions approved baseline blind blinded Blinding block Breastfeeding Caregivers cell proliferation childbearing potential clinical clinical outcomes clinically suspected college comparator completion Compliance Concomitant medication Contraception Controlled trial coronavirus COVID-19 COVID-19 disease COVID-19 pneumonia CPAP CRP Data monitoring committee Day death defined Desaturation determine diagnosed disease disease severity dissemination dose drug ECMO effective Efficacy element English enrolment exclusion experimental arm experimental intervention facemask FOS fostamatinib generate GRADE grade 3 Graft graft-versus-host-disease hepatic dysfunction hospital Hospital admission Hospital stay hospitalisation hospitalised patient Hospitalised patients Immune thrombocytopenia Imperial College Healthcare NHS Trust incidence information Informed consent inhibitor Inpatient Inpatients Intervention invasive Invasive mechanical ventilation invasive ventilation investigational agent investigator JAK1 JAK2 janus kinase Kinase inhibitor kinases Laboratory male participants MATIS Mild minimum moderate Moderate COVID-19 moderate to severe Modification multi-arm myelofibrosis nasal oxygen NHS Non-invasive non-invasive ventilation number objective Obstructive obstructive sleep apnoea opinion Ordinal Scale outcome oxygen Pairwise comparison pandemic parallel-group participant Patient Pneumonia polycythaemia vera principal investigator product progression promise proportion protocol random randomisation randomised randomised controlled trial receiving recruit recruited reduce reduce mortality reducing renal impairment renal replacement therapy replacement therapy required Requirement ruxolitinib Sample size sample size calculation Sample size calculations SARS-CoV2 infection scale Secondary objectives selective sequence severe allergic reaction Severe COVID-19 pneumonia severity severity of COVID-19 sexual intercourse signal sleep apnoea Sperm sperm donation spleen Splenomegaly Stage stage 2 Standard Standard of care statistical analysis status Stratification study drug Study protocol supplementary material Symptom systemic inflammation the WHO therapy thrombocytopenia translation Treatment Trial Trial registration Trust tyrosine tyrosine kinase inhibitor Venous Thromboembolism verbal website WHO with COVID-19
[DOI] 10.1186/s13063-021-05190-z PMC 바로가기 [Article Type] Letter

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

입원한 COVID-19 환자의 치료에서 우수한 코르티코스테로이드인 Methylprednisolone 또는 dexamethasone: 삼중 맹검 무작위 대조 시험

Research Article

Published on 2021-04-102022-07-28
Journal: BMC Infectious Diseases [Category] 임상,

[키워드] Admission clinical status conducted control group control groups coronavirus disease Coronavirus disease 2019 Corticosteroid COVID-19 COVID-19 patients death demonstrated Dexamethasone dose Effectiveness enrolled group Hospital stay Hospitalized hospitalized COVID-19 hospitalized COVID-19 patient hospitalized COVID-19 patients hypoxic Intervention intervention group Iran measure Methylprednisolone no significant difference no significant differences on admission Ordinal Scale outbreak Patient Randomized controlled trial Randomly receive Registered remained Result significant difference significantly significantly lower Treatment treatment of COVID-19 Trial Trial registration two group two groups uninfected Vaccine ventilator were assessed WHO ordinal scale
PMC 바로가기 [Article Type] Research Article

What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak

토실리주맙은 어떻습니까? COVID-19 발생 기간 동안 NYC 병원의 후향적 연구

Randomized Controlled Trial

Published on 2021-04-082022-08-13
Journal: PLoS ONE [Category] MERS, SARS, 임상, 진단,

[키워드] 7-point ordinal scale 95% CI absence Admission Bacterial infection Bacterial infections bacterial superinfection bacterial superinfections baseline Control Corticosteroid Corticosteroids COVID-19 COVID-19 outbreak demographics Endpoint evaluated Evidence evidence of gastrointestinal perforation Health hospital Hypoxemia Illness severity incidence include increase in independent independent of inflammatory phase interleukin-6 interleukin-6 receptor large academic medical center measure Methylprednisolone New York City no evidence of no increase Ordinal Scale outcome Oxygenation Patient patients with COVID-19 primary endpoint primary endpoints Primary outcomes receiving receptor blocker Result Retrospective analysis Retrospective study secondary secondary bacterial infection Secondary bacterial infections Secondary endpoints severe disease Support t-test Tocilizumab ventilator ventilator free survival ventilator-free survival
[DOI] 10.1371/journal.pone.0249349 PMC 바로가기 [Article Type] Randomized Controlled Trial

Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety

입원한 코로나19 환자의 토실리주맙: 임상 결과, 염증 마커 동역학 및 안전성

Observational Study

Published on 2021-04-012022-09-11
Journal: Journal of medical virology [Category] MERS, SARS, 임상, 진단, 치료기술,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted hazard ratio baseline benefit C-reactive protein cause clinical Clinical improvement Comorbidity conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Cox proportional-hazards model cytopenias defined detect discharge evaluated fibrinogen hospitalized patient hospitalized patients immunomodulatory IMPROVE Infection Inflammation Inflammatory interleukin-6 interleukin-6 receptor marker morbidity Mortality Ordinal Scale outcome outcomes oxygen Oxygen requirements Patient Probability proportion receive receiving receptor antagonist reduced reduction in requiring supplemental oxygen respiratory Retrospective study SARS-CoV-2 severe acute respiratory syndrome Coronavirus severity subsequent infections supplemental oxygen survival temperature Tocilizumab transaminitis Treatment University of Washington Weighting with COVID-19
[DOI] 10.1002/jmv.26674 PMC 바로가기 [Article Type] Observational Study

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study

중등도 COVID-19에서 페길화된 인터페론 알파-2b의 효능 및 안전성: A상, 무작위, 대조, 공개 라벨 연구

Clinical Trial

Published on 2021-04-012022-09-11
Journal: International Journal of Infectious Diseases [Category] SARS, 임상, 치료제,